Inaya Therapeutics is a privately-held biopharmaceutical company focused on developing breakthrough inhaled therapies with the potential to significantly improve current treatment paradigms for rare cardiopulmonary conditions. The team collectively brings decades of experience in successfully developing cardiopulmonary, inhaled and/or other therapies on a variety of advanced platforms, and includes world class expertise in clinical, pre-clinical, commercial, CMC, corporate development, regulatory/quality and intellectual property. The company is developing a pipeline of therapies for PAH as well as other cardiopulmonary indications.
Company Details
- Founded
- 2023
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.inayatx.com
- Keywords
- in clinical.
Inaya Therapeutics Questions
Inaya Therapeutics's website is http://www.inayatx.com
Inaya Therapeutics's LinkedIn profile is https://www.linkedin.com/company/inayatx
Inaya Therapeutics's industry is
Biotechnology Research
Inaya Therapeutics's top competitors are
Ropirio Therapeutics, Inc.,
Candid Therapeutics,
Biotech Ceo Sisterhood,
Ovid Therapeutics,
Biotechnology Innovation Organization,
Voyager Therapeutics, Inc.,
Seaport Therapeutics,
Biotechtv,
Bloom Science, Inc.,
Incarda Therapeutics.
Inaya Therapeutics's categories are Biotechnology Research
Inaya Therapeutics's founding year is 2023
